News
IMAB
1.800
-0.55%
-0.010
I-Mab Announces CMO Transition, Interim Successor Named
I-Mab has announced the resignation of their Chief Medical Officer Dr. John Hayslip. The company has engaged a new chief medical officer in the interim. The search for a permanent successor is currently underway. IMAB stock is down 10% in the last week.
TipRanks · 3d ago
Weekly Report: what happened at IMAB last week (0408-0412)?
Weekly Report · 3d ago
I-Mab Price Target Maintained With a $6.00/Share by Needham
Dow Jones · 6d ago
I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline
Needham analyst Gil Blum maintained a Buy rating on I-MAB (IMAB – Research Report) today and set a price target of $6.00. The company is a clinical stage biopharmaceutical company developing treatments for cancers and autoimmune disorders. Blum believes the company is well-positioned for growth.
TipRanks · 6d ago
Weekly Report: what happened at IMAB last week (0401-0405)?
Weekly Report · 04/08 10:19
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. I-Mab is a U.S.-based, global biotech company focused on the development and potential commercialization of immunotherapies for the treatment of cancer.
Barchart · 04/05 06:00
I-Mab Finalizes Divestiture and Resolves Obligations
TipRanks · 04/02 21:59
I-MAB ANNOUNCES CLOSING OF THE DIVESTITURE OF BUSINESS OPERATIONS IN CHINA
Reuters · 04/02 20:01
I-Mab Announces Major Leadership Reshuffle
TipRanks · 04/01 13:57
Weekly Report: what happened at IMAB last week (0325-0329)?
Weekly Report · 04/01 10:18
Weekly Report: what happened at IMAB last week (0318-0322)?
Weekly Report · 03/25 10:20
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
B of A Securities cut the price target for Li Auto Inc. (NASDAQ:LI) on Friday. Goldman Sachs cut Tesla, Inc. Price target from $220 to $190. Cantor Fitzgerald raised Micron Technology's price target to $120. The price target was raised for I-Mab and CoStar Group.
Benzinga · 03/18 11:52
I-Mab Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/18 11:27
Piper Sandler Maintains Overweight on I-MAB, Lowers Price Target to $10
Benzinga · 03/18 11:16
I-Mab Price Target Cut to $8.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 03/18 10:51
HC Wainwright & Co. Reiterates Buy on I-MAB, Lowers Price Target to $8
Benzinga · 03/18 10:41
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
TipRanks · 03/18 10:20
Weekly Report: what happened at IMAB last week (0311-0315)?
Weekly Report · 03/18 10:18
I-Mab Is Maintained at Buy by Needham
Dow Jones · 03/15 13:39
I-Mab Price Target Cut to $6.00/Share From $8.00 by Needham
Dow Jones · 03/15 13:39
More
Webull provides a variety of real-time IMAB stock news. You can receive the latest news about I-Mab through multiple platforms. This information may help you make smarter investment decisions.
About IMAB
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.